US2005107291A1PendingUtilityA1

Compositions and methods for treating or preventing diseases of body passageways

62
Assignee: UNIV BRITISH COLMUMBIAPriority: May 24, 1996Filed: Oct 20, 2004Published: May 19, 2005
Est. expiryMay 24, 2016(expired)· nominal 20-yr term from priority
Inventors:William L. HunterLindsay Machan
A61P 31/04A61P 35/00A61P 9/10A61P 43/00A61P 31/06A61P 9/00A61P 27/02A61K 9/1635A61K 9/5146A61K 9/10A61K 31/28A61P 13/02A61P 11/00A61K 9/5153A61K 47/34A61P 1/00A61K 31/337A61K 9/12A61K 9/1075A61K 9/70A61P 1/04A61P 13/00A61K 9/5031A61P 11/08A61K 9/167A61K 9/1652A61K 9/7007A61K 31/335A61K 31/00A61K 9/0024A61K 9/1647A61K 9/5192A61K 9/5138A61P 13/08A61P 15/00A61K 33/24
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides methods for treating or preventing diseases associated with body passageways, comprising the step of delivering to an external portion of the body passageway a therapeutic agent. Representative examples of therapeutic agents include anti-angiogenic factors, anti-proliferative agents, anti-inflammatory agents, and antibiotics.

Claims

exact text as granted — not AI-modified
1 . A method for treating or preventing an inflammatory disease associated with narrowing or obstruction of a body passageway, comprising delivering to an external portion of the body passageway of a patient in need thereof a therapeutically effective amount of an anti-inflammatory or immunosuppressive agent or a composition comprising an anti-inflammatory or immunosuppressive agent, such that the inflammatory disease is treated.  
     
     
         2 . The method of  claim 1  wherein the inflammatory disease is a gastrointestinal tract disease.  
     
     
         3 . The method of  claim 2  wherein the gastrointestinal tract disease is selected from the group consisting of pancreatitis, Crohn's Disease, Ulcerative Colitis, Ulcerative Proctitis, and Primary Sclerosing Cholangitis.  
     
     
         4 . The method of  claim 2  wherein the gastrointestinal tract disease is a benign stricture.  
     
     
         5 . The method of  claim 4  wherein the benign stricture is selected from the group consisting of bile duct, esophagus, duodenum, small bowel and colon strictures.  
     
     
         6 . The method of  claim 1  wherein the inflammatory disease is vasculitis.  
     
     
         7 . The method of  claim 1  wherein the inflammatory disease is a respiratory tract disease.  
     
     
         8 . The method of  claim 7  wherein the respiratory tract disease is asthma, hypersensitivity pneumonitis, asbestosis, silicosis, chronic bronchitis, or chronic obstructive airway disease.  
     
     
         9 . The method of  claim 1  wherein the inflammatory disease is a nasolacrimal duct or eustachean tube disease.  
     
     
         10 . The method of  claim 9  wherein the nasolacrimal duct or eustachean tube disease is a stricture.  
     
     
         11 . The method of  claim 1  wherein the body passageway is selected from the group consisting of lacrimal ducts, trachea, bronchi, bronchiole, nasal airways, sinus passages, eustachian tubes, and external auditory canal.  
     
     
         12 . The method of  claim 1  wherein the body passageway is selected from the group consisting of an esophagus, a stomach, a duodenum, a small intestine, a large intestine, biliary tracts, a ureter, a bladder, and a urethra.  
     
     
         13 . The method of  claim 1  wherein the anti-inflammatory agent is a non-steroidal anti-inflammatory agent (NSAID).  
     
     
         14 . The method of  claim 13  wherein the NSAID is selected from the group consisting of salicylates, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, mefenamic acid, nabumetone, naproxen, piroxicam, phenylbutazone, ketoprofen, S-ketoprofen, ketorolac tromethamine, sulindac, and tolmetin.  
     
     
         15 . The method of  claim 14  wherein the salicylate is selected from the group consisting of salsalate, mesalamine, diflunisal, and choline magnesium trisalicylate.  
     
     
         16 . The method of  claim 1  wherein the anti-inflammatory agent is a steroidal agent.  
     
     
         17 . The method of  claim 16  wherein the steroidal agent is selected from the group consisting of beclomethasone, betamethasone, cortisone, dexamethasone, fluocinolone, flunisolide, fluticasone proprionate, fluorinated-corticoids, triamcinolone-diacetate, hydorcortisone, prednisolone, methylprednisolone and prednisone.  
     
     
         18 . The method of  claim 1  wherein the immunosuppressive agent is an adrenocorticosteroid or cyclosporine.  
     
     
         19 . The method of  claim 1  wherein the composition is biodegradable.  
     
     
         20 . The method of  claim 1  wherein the composition is non-biodegradable.  
     
     
         21 . The method of  claim 1  wherein the composition further comprises a polymer.  
     
     
         22 . The method of  claim 21  wherein the polymer is biodegradable.  
     
     
         23 . The method of  claim 21  wherein the polymer is non-biodegradable.  
     
     
         24 . The method of  claim 1  wherein the composition further comprises a copolymer of lactic acid and glycolic acid.  
     
     
         25 . The method of  claim 1  wherein the composition further comprises a poly(caprolactone).  
     
     
         26 . The method of  claim 1  wherein the composition further comprises a poly(lactic acid).  
     
     
         27 . The method of  claim 1  wherein the composition further comprises a copolymer of poly(lactic acid) and poly(caprolactone).  
     
     
         28 . The method of  claim 1  wherein the composition further comprises a poly(ethylene-vinyl acetate).  
     
     
         29 . The method of  claim 1  wherein the composition further comprises a polyester.  
     
     
         30 . The method of  claim 1  wherein the composition further comprises a polyurethane.  
     
     
         31 . The method of  claim 1  wherein the composition further comprises a polyanhydride.  
     
     
         32 . The method of  claim 1  wherein the composition further comprises a gelatin.  
     
     
         33 . The method of  claim 1  wherein the composition is in the form of a paste.  
     
     
         34 . The method of  claim 1  wherein the composition is in the form of a film.  
     
     
         35 . The method of  claim 1  wherein the composition is in the form of a spray.  
     
     
         36 . The method of  claim 1  wherein the composition comprises microspheres having an average size ranging from about 0.5 μm to 200 μm.  
     
     
         37 . The method of  claim 1  wherein the anti-inflammatory or immunosuppressive agent or the composition comprising the anti-inflammatory or immunosuppressive agent is administered percutaneously to an exterior surface of the body passageway.  
     
     
         38 . The method of  claim 1  wherein the anti-inflammatory or immunosuppressive agent or the composition comprising the anti-inflammatory or immunosuppressive agent is applied to an adventitial surface of the body passageway.  
     
     
         39 . A method for treating or preventing an inflammatory disease associated with narrowing or obstruction of a body passageway, comprising delivering to smooth muscle cells via the adventitia of the body passageway of a patient in need thereof a therapeutically effective amount of an anti-inflammatory or immunosuppressive agent or a composition comprising an anti-inflammatory or immunosuppressive agent, such that the inflammatory disease is treated.  
     
     
         40 . The method of  claim 39  wherein the inflammatory disease is a gastrointestinal tract disease.  
     
     
         41 . The method of  claim 40  wherein the gastrointestinal tract disease is selected from the group consisting of pancreatitis, Crohn's Disease, Ulcerative Colitis, Ulcerative Proctitis, and Primary Sclerosing Cholangitis.  
     
     
         42 . The method of  claim 40  wherein the gastrointestinal tract disease is a benign stricture.  
     
     
         43 . The method of  claim 42  wherein the benign stricture is selected from the group consisting of bile duct, esophagus, duodenum, small bowel and colon strictures.  
     
     
         44 . The method of  claim 39  wherein the inflammatory disease is vasculitis.  
     
     
         45 . The method of  claim 39  wherein the inflammatory disease is a respiratory tract disease.  
     
     
         46 . The method of  claim 45  wherein the respiratory tract disease is asthma, hypersensitivity pneumonitis, asbestosis, silicosis, chronic bronchitis, or chronic obstructive airway disease.  
     
     
         47 . The method of  claim 39  wherein the inflammatory disease is a nasolacrimal duct or eustachean tube disease.  
     
     
         48 . The method of  claim 47  wherein the nasolacrimal duct or eustachean tube disease is a stricture.  
     
     
         49 . The method of  claim 39  wherein the body passageway is selected from the group consisting of lacrimal ducts, trachea, bronchi, bronchiole, nasal airways, sinus passages, eustachian tubes, and external auditory canal.  
     
     
         50 . The method of  claim 39  wherein the body passageway is selected from the group consisting of an esophagus, a stomach, a duodenum, a small intestine, a large intestine, biliary tracts, a ureter, a bladder, and a urethra.  
     
     
         51 . The method of  claim 39  wherein the anti-inflammatory agent is a non-steroidal anti-inflammatory agent (NSAID).  
     
     
         52 . The method of  claim 51  wherein the NSAID is selected from the group consisting of salicylates, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, mefenamic acid, nabumetone, naproxen, piroxicam, phenylbutazone, ketoprofen, S-ketoprofen, ketorolac tromethamine, sulindac, and tolmetin.  
     
     
         53 . The method of  claim 52  wherein the salicylate is selected from the group consisting of salsalate, mesalamine, diflunisal, and choline magnesium trisalicylate.  
     
     
         54 . The method of  claim 39  wherein the anti-inflammatory agent is a steroidal agent.  
     
     
         55 . The method of  claim 54  wherein the steroidal agent is selected from the group consisting of beclomethasone, betamethasone, cortisone, dexamethasone, fluocinolone, flunisolide, fluticasone proprionate, fluorinated-corticoids, triamcinolone-diacetate, hydorcortisone, prednisolone, methylprednisolone and prednisone.  
     
     
         56 . The method of  claim 39  wherein the immunosuppressive agent is an adrenocorticosteroid or cyclosporine.  
     
     
         57 . The method of  claim 39  wherein the composition is biodegradable.  
     
     
         58 . The method of  claim 39  wherein the composition is non-biodegradable.  
     
     
         59 . The method of  claim 39  wherein the composition further comprises a polymer.  
     
     
         60 . The method of  claim 59  wherein the polymer is biodegradable.  
     
     
         61 . The method of  claim 59  wherein the polymer is non-biodegradable.  
     
     
         62 . The method of  claim 39  wherein the composition further comprises a copolymer of lactic acid and glycolic acid.  
     
     
         63 . The method of  claim 39  wherein the composition further comprises a poly(caprolactone).  
     
     
         64 . The method of  claim 39  wherein the composition further comprises a poly(lactic acid).  
     
     
         65 . The method of  claim 39  wherein the composition further comprises a copolymer of poly(lactic acid) and poly(caprolactone).  
     
     
         66 . The method of  claim 39  wherein the composition further comprises a poly(ethylene-vinyl acetate).  
     
     
         67 . The method of  claim 39  wherein the composition further comprises a polyester.  
     
     
         68 . The method of  claim 39  wherein the composition further comprises a polyurethane.  
     
     
         69 . The method of  claim 39  wherein the composition further comprises a polyanhydride.  
     
     
         70 . The method of  claim 39  wherein the composition further comprises a gelatin.  
     
     
         71 . The method of  claim 39  wherein the composition is in the form of a paste.  
     
     
         72 . The method of  claim 39  wherein the composition is in the form of a film.  
     
     
         73 . The method of  claim 39  wherein the composition is in the form of a spray.  
     
     
         74 . The method of  claim 39  wherein the composition comprises microspheres having an average size ranging from about 0.5 μm to 200 μm.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.